Fresh analysis reveals that patients who stop using new GLP-1 drugs like Mounjaro or Wegovy may regain reduced body mass far faster than those who end traditional lifestyle programs.
Published data in a prominent health publication demonstrates that while overweight people often shed about a fifth of their body weight while on the medication, the mass returns at an estimated rate of nearly a kilo each month upon discontinuation.
"People buying these drugs should be aware of the danger of fast rebound weight gain when the therapy ends," cautioned lead investigator Dr. Susan Jebb.
This pace of regain implies a reversion to starting mass in about one and a half years.
Comparing Therapies
The research, which looked at 37 of studies involving over 9,000 of patients, contrasted the outcomes of GLP-1 agonists with other pills.
The team note that people who lose weight through diet and exercise typically have a slower weight regain—around 100 grams monthly—after stopping.
The Reason for the Fast Regain
Nutrition scientists propose the mode of action of the injections is key to understanding the amplified regain.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.
"Sustained high doses of the hormone concentrations far above than normal may cause the body to produce less of its own natural hormone, and may also lessen sensitivity to its effects," noted Dr. Adam Collins, a dietetics expert.
"Withdrawal of this medication leads to hunger is unsuppressed, making excessive eating much more probable."
A Chronic Disease?
Health authorities recommend the jabs for people with obesity-related medical conditions, accompanied by recommended lifestyle changes.
Many experts say that, considering the significant potential of weight regain, the treatment should be considered long-term.
This opinion is supported by drug manufacturers, who state that the findings "underscore the persistent character of excess weight," akin to managing diseases like high blood pressure.
Patient Experiences
Individuals who have stopped the jabs explain a intense return of hunger.
"It was like something that goes on and you're instantly starving," recalled an individual.
The struggle is compounded if individuals have not developed permanent dietary or behavioural changes during therapy.
Significant Adoption
Figures suggest that a significant number of adults in the UK have tried these injections in the past year, with desire remaining high.
- Adoption is more common among women than males.
- The middle-aged demographic shows the greatest usage rates.
- Many obtain the drugs through private prescriptions rather than public health services.
In conclusion, clinicians stress that while the jabs are effective agents for shedding pounds, they are not a magic solution and maintained weight loss likely depends on ongoing behavioural management.
